Immunotherapy-based targeting of MSLN(+) activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis

We investigated the role of mesothelin (Msln) and thymocyte differentiation antigen 1 (Thy1) in the activation of fibroblasts across multiple organs and demonstrated that Msln(−/−) mice are protected from cholestatic fibrosis caused by Mdr2 (multidrug resistance gene 2) deficiency, bleomycin-induced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Nishio, Takahiro, Koyama, Yukinori, Liu, Xiao, Rosenthal, Sara B., Yamamoto, Gen, Fuji, Hiroaki, Baglieri, Jacopo, Li, Na, Brenner, Laura N., Iwaisako, Keiko, Taura, Kojiro, Hagood, James S., LaRusso, Nicholas F., Bera, Tapan K., Pastan, Ira, Brenner, David A., Kisseleva, Tatiana
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2021
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8307749/
https://ncbi.nlm.nih.gov/pubmed/34253615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.2101270118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados